Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.
S. Branford, D. Yeung, W. Parker, Nicola D. Roberts +14 more
2014Blood201 citations
Semantic Scholar
Researcher profile · Semantic Scholar
S. Branford, D. Yeung, W. Parker, Nicola D. Roberts +14 more
S. Branford, D. Yeung, D. Ross, Jodi A. Prime +12 more
W. Parker, S. Phillis, D. Yeung, T. Hughes +2 more
M. Caruso, J. Moore, G. Goodall, Michelle L. Thomas +6 more
D. Yeung, W. Parker, S. Phillis, Jasmina Georgievski +3 more
W. Parker, S. Phillis, D. Yeung, T. Hughes +2 more